Methylation Analysis in Kidney Tumors
Author Information
Author(s): Costa Vera L, Henrique Rui, Ribeiro Franclim R, Pinto Mafalda, Oliveira Jorge, Lobo Francisco, Teixeira Manuel R, Jerónimo Carmen
Primary Institution: Portuguese Oncology Institute, Porto, Portugal
Hypothesis
Can a gene promoter methylation panel identify prevalent types of renal cell tumors?
Conclusion
Differential methylation levels of CDH1, PTGS2, and RASSF1A can help distinguish between common renal tumors.
Supporting Evidence
- Methylation levels were significantly different among the four subtypes of renal tumors.
- CDH1 hypermethylation was higher in clear cell RCC compared to chromophobe RCC and oncocytoma.
- RASSF1A methylation levels were higher in papillary RCC than in normal tissue.
Takeaway
This study looked at how certain genes are changed in kidney tumors, which can help doctors tell different types of kidney cancer apart.
Methodology
Quantitative methylation-specific PCR was used to analyze 18 gene promoters in tumor and normal tissue samples.
Limitations
No significant differences in methylation levels between normal and neoplastic renal tissues were found, except for RASSF1A in pRCC.
Participant Demographics
The study included 85 patients, with 61.2% male and a median age of 61 years.
Statistical Information
P-Value
p = 0.0007 for CDH1, p = 0.002 for PTGS2, p = 0.0001 for RASSF1A
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website